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Abstract
Construction of a library of structurally diverse diazenecarboxamide-extended cis-[Pt(2-picolyl-1,2,3-triazole)Cl2] and
cis-[Pt(propan-1,3-diamine)CBDCA] (CBDCA = 1,1-cyclobutanedicarboxylate) complexes 1–4 is described. These
compounds retain oxidative properties of parent diazenecarboxamides against glutathione as demonstrated by NMR
spectroscopy and high resolution mass spectrometry experiments. Cytotoxic activity of 1–4 was investigated against hu-
man cervical carcinoma HeLa cells. Four library members were found to possess moderate cytotoxic activity. Some mo-
del compounds were also examined, returning [PtCl2L2] (L = 1-(2-picolyl)-4-phenyl-1H-1,2,3-triazole) as the most po-
tent under this investigation with IC50 of 19.05 μM, comparable to that of cisplatin (IC50 = 16.3 μM).
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1. Introduction
Cisplatin, cis-[diamminedichloridoplatinum(II)]
(Figure 1), has been clinically approved for many years to
be used as a single agent or in combination with other an-
ti-cancer drugs to treat solid tumors including lung carci-
noma, cervical carcinoma, head and neck tumors, as well
as carcinoma of ovaries, bladder and testis.1 Despite the
fact that it is one of the most effective and commonly used
agents, nephro-, neuro- and ototoxicities are the main side
effects of this drug.2 Its major obstacle to successful che-
motherapy, significantly reducing the effectiveness of the
cancer treatment, is development of cisplatin-resistance in
tumors. Cisplatin-resistance is multifactorial, i.e. it is ba-
sed on several molecular mechanisms.3 Among others, it
can emerge as a result of increased inactivation of cispla-
tin by intracellular thiol-containing molecules, such as
glutathione (GSH).3a,b Increased GSH level may cause re-
sistance by binding/inactivating cisplatin, enhancing
DNA repair or reducing cisplatin-induced oxidative
stress.3c Glutathion-S-transferase (GST) may augment the
resistance by catalyzing GSH-cisplatin binding. The in-
creased expression of GST along with elevated GSH level
in resistant tumor cells suggests that the increased inacti-
vation of cisplatin contributes significantly to the resistan-
ce phenotype.3a,b
In so advanced diseases such as cancer it is unli-
kely that a single mono functional targeted drug would
be sufficient to cure the cancer. Combined drugs (cock-
tails) that impact multiple targets simultaneously are bet-
ter at controlling complex disease systems and are the
standard of care in cancer treatment.4 In order to further
improve the efficiency of using a two-drug cocktail, one
approach involves the use of the so-called hybrid mole-
cules, which comprises the incorporation of two drugs
covalently bound into a single entity that combines phar-
macological effects of independently acting drugs.4,5 For
such molecules, it has been even demonstrated that supe-
rior synergistic effects can be achieved that is beyond
mere simultaneous administration of two separate
agents.6 An important example of hybrid molecules in
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the field of metal-based anticancer drugs includes the
development of platinum complexes having bioactive
carrier ligands, which are capable to revert resistances
that tumor cells acquire during chemotherapy. This has
been exemplified by ethacraplatin (A, Figure 1) in which
GST-inhibitory ethacrynic acid was attached to the plati-
num,7 as well as platinum complexes of nitrofuran car-
bohydrazide (B, Figure 1),8 which is a human thioredo-
xin reductase inhibitor. 
We have shown previously that diazenecarboxami-
des9 (Figure 2) are cytotoxic for different tumor cell lines
and act synergistically with cisplatin.10 These compounds
are powerful modulators of intracellular GSH concentra-
tion.10a,c,e In a combined (cocktail) diazenecarboxami-
de–cisplatin treatment, the GSH-depleting diazenecarbo-
xamides led to the reversal of the acquired tumor resistan-
ces. The synergistic effect with cisplatin was shown on dif-
ferent tumor-cell lines as well as some cisplatin-resistant
sublines.10c,i,11 Besides the GSH-depleting activity, in se-
lected examples an activation some alternative cell-death
pathways has been observed, indicating that GSH may not
be the only cellular target of diazenecarboxamides.10h
The above results prompted design and screening
an array of different diazenecarboxamide-extended plati-
num complexes. For these hybrid molecules a dual targe-
ting that combines the advantages of diazenecarboxami-
de and cisplatin (and carboplatin) structural motif is ex-
pected. However, the synthesis of a diverse library of li-
gand-arm functionalized diazenecarboxamides that are
capable of binding to platinum(II), as well as the corres-
ponding complexes, is expected to be cumbersome and
associated with redesign of synthetic routes for any spe-
cific type of the molecule. To increase the efficacy of the
preparation of such a library of compounds we12–15and ot-
hers16 developed strategies that are based on recently dis-
covered copper-catalyzed azide-alkyne cycloaddition
protocol,17,18 also known as “Click chemistry”, as outli-
ned in Scheme 1.19
Figure 1. The structure of cisplatin, carboplatin and selected hybrid molecules.
Figure 2. Diazenecarboxamides
Scheme 1. Schematic representations of the linear strategy versus the convergent strategy.
Figure 3 Diazenecarboxamide-extended platinum complexes
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2. Results and Discussion
We have designed and prepared four types of diaze-
necarboxamide-extended platinum complexes, which dif-
fer in i. functionality R, ii. ligand arm that coordinates to
platinum and consequently iii. platinum(II) coordination
environment, and iv. linker that joins the diazenecarboxa-
mide and complex parts together (Figure 3). Briefly, it has
been demonstrated that the oxidative properties of diaze-
necarboxamides can be modulated through the choice of
group R attached directly to the diazene –N=N– moiety,20
whereas specific hydrolytic and coordinative properties
towards DNA of tumor cells can be tuned by ligand varia-
tion around platinum center. Finally, through the choice of
the linker, one can in principle adjust the lipophilicity of
the compound, an important pharmacological characteri-
stic that correlates with cellular uptake of a drug.21
The syntheses of compounds 1–4 were accomplis-
hed through the strategies shown in Scheme 1.12–15 More
specifically, the synthetic routes are outlined in Scheme 2.
Following the linear strategy shown in Scheme 1
propargyl functionalized diezenecarboxamides 5 were by
copper-catalyzed azide-alkyne cycloaddition (“Click che-
mistry”) with picolyl azide transformed into the corres-
ponding picolyl-triazole derivatives 6 (Scheme 2).12,15 Alt-
hough the power of this strategy lies in potential combina-
torial approach to diazenecarboxamides, conjugated with
different ligand-arms, by using different organoazides, at
this point of the research we only used picolyl azide as a
“click” partner. In the final stage, the ability of picolyl-tria-
zole group at 6 to serve as bidentate ligand22,23 was emplo-
yed to access the desired platinum-diazenecarboxamide
conjugates 1 and 2 of cis-[Pt(diamine)Cl2] structure.13
Concerning the coordination chemistry, this is a
“classical” strategy, which considers the ligand to metal
coordination at the very last step. The major drawback of
this linear strategy is a potential redesign of synthetic rou-
tes for any specific type of the ligand. Alternatively, con-
vergent strategy relies on the post-functionalization of
metal complexes with the introduction of specific features
Figure 3. Diazenecarboxamide-extended platinum complexes. 
Scheme 2. Selected details showing the preparation of diazenecarboxamide-extended platinum complexes 1–4 using the strategies presented in
Scheme 1.
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at the very last step (Scheme 1). Following this convergent
strategy, “click” reaction between propargyl functionali-
zed diezenecarboxamides 5 and azide-tagged platinum(II)
complex 7 allowed post-functionalization directly into the
metalated “click” cycloadducts 3 and 4 of structure cis-
[Pt(diamine)CBDCA] (CBDCA = 1,1-cyclobutanedicar-
boxylate) (Scheme 2).14
The oxidative properties of diazenecarboxamide
moiety in complexes 1–4 towards GSH is preserved as de-
monstrated by the following experiment. Compound 3b
and slight excess of GSH (3.7 mol equiv.) were dissolved
in a mixture of DMF-d7 and D2O at 23 °C. The progress of
the reaction shown in Scheme 3 was monitored by 1H
NMR spectroscopy. Figure 4 demonstrates clean and fast
transformation of diazenecarboxamide 3b and GSH into
semicarbazide 3bRED and GSSG. The resulting reaction
mixture after the NMR experiment was analyzed by ESI+
LC-MS spectrometry, which confirmed the presence of
semicarbazide 3bRED (m/z found for C26H30F3N8O6Pt
+
[M + H]+ = 802.1886) and GSSG (See Experimental).
To ascertain the oxidative properties of 3b under
biological conditions, it was incubated with GSH (4.4 mol
equiv.) in a mixture of DMSO and growth medium sup-
plemented with 10% fetal serum (Experimental). Similar
conditions were used for determination of 3b cytotoxicity
(vide infra). Analysis of the reaction mixture by ESI+ 
LC-MS revealed nearly quantitative conversion of 3b into
3bRED within 3.5 hours.
Scheme 3. Oxidation of GSH with diazenecarboxamide 3b into GSSG and semicarbazide 3bRED. 
Figure 4. Monitoring the course of the reaction from Scheme 3 between 3b (6.7 mM) and GSH (24.7 mM) in a mixture of DMF-d7 (0.50 mL) and
D2O (0.25 mL) at 23 °C by 
1H NMR spectroscopy. Spectra shown after a) 6 min, b) 11 h, and c) 43 h of the reaction. Well separated resonances of
3b (o), 3bRED (*), and GSSG (Δ) are indicated. Diagram d) shows the progress of the reaction as determined by integration of resonances of 3b and
3bRED. 
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Compounds 1–4 were tested using MTT assay for
their in vitro anticancer activity against human cervical
carcinoma HeLa cells (see Experimental section for de-
tails). The results for compounds 1 and 2 (Table 1) with
cis-[diamminedichloroplatinum(II)] coordination sphere
were compared to cisplatin (Table 2). In analogy, the re-
sults for compounds 3 and 4 with cis-[Pt(diamine) 
CBDCA] structure were compared to carboplatin. Com-
pounds 2a and 2b having strongly electron-withdrawing
p-nitrophenyl and p-(trifluoromethyl)phenyl substituents
attached to the diazene –N=N– group were quite cytoto-
xic. Interestingly, this was not the case for 3a and 3b from
the carboplatin-like series, where 3d and 4e were the most
active compounds. 
Table 2. Cytotoxic activity of cisplatin, carboplatin, 6a, 6b, 7, and
8 against cervical carcinoma HeLa cells expressed as IC50 values
(μM) obtained after 72 h incubation. 
Compound IC50 (μM)
Cisplatin 16.3 ± 3.6
Carboplatin 441.1 ± 91.8
22.33 ± 3.19 
162.40 ± 21.98
>1000
19.05
Table 1. Cytotoxic activity of complexes 1–4 against cervical carcinoma HeLa cells expressed as IC50 values
(μM) obtained after 72 h incubation. 
R 1 IC50 2 IC50 3 IC50 4 IC50
4-NO2-C6H4- 1a >300 2a 87 3a >1000
4-CF3-C6H4- 1b 300 2b 277 3b >1000
C6F5- 1c >300
4-Cl-C6H4- 1d >300 2d >300 3d 614 ± 161.9
4-F-C6H4- 2e >300 4e 649.6
4-CH3-C6H4- 4f >1000
4-CH3O-C6H4- 4g 990
In attempt to experimentally evaluate this idea of
combining separate components into hybrid molecules
1–4, cytotoxic activities of compounds 6a, 6b, 7 and 8
were determined. The results are summarized in Table 2.
cis-[Pt(2-azidopropan-1,3-diamine)CBDCA] (7) proved
to be inactive. Unexpectedly, uncoordinated picolyl-tria-
zole functionalized diazenecarboxamides 6a and 6b (IC50
= 22.33 μM and 162.40 μM, respectively) as well as mo-
del [Pt(picolyl-triazole)Cl2] complex 8 (IC50 = 19.05 μM)
were all more active than the corresponding hybrids 2a
and 2b (IC50 = 78 μM and 277 μM). The activity of 8 was
in the range of cisplatin (IC50 = 16.3 μM). 
An easy explanation for severely reduced activity of
1–2 when coming from their “parent” compounds 6 and 8
is impossible but it could be a result of change in lipophi-
licity, molecular size, shape, etc.24 Before these factors are
taken into the consideration, however, the issue of solubi-
lity has to be addressed first as compounds 1–4 are com-
pletely insoluble in water. 
3. Conclusions
We have demonstrated a design of a library of diaze-
necarboxamide-extended cisplatin and carboplatin analo-
gues. The advantage of this strategy is modular, combina-
torial approach, taking advantages of “Click chemistry”
and offering timely preparation of organic-inorganic co-
njugates in general. The library was designed and evalua-
ted for improved efficiency in antitumor therapy. Alt-
hough several members were quite cytotoxic, in contrast
to expectations, none performed better than carboplatin or
cisplatin. This can be due to their limited solubility. Work
is in progress to diazenecarboxamide-extended cisplatin
and carboplatin analogues with improved water solubility.
4. Experimental
4. 1. General
Cisplatin, carboplatin and NMR solvents were used
as obtained from commercial sources (Sigma-Aldrich,
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USA). Compounds 1,13 2,13 3,14 4,14 5,15 6,22 and 714 and
822 were prepared as described in the literature. NMR
spectra were measured on a Bruker Avance III 500 spec-
trometer, using Si(CH3)4 as internal standard. ESI+
HRMS spectra were recorded with Agilent 6224 Accurate
Mass TOF LC/MS system. 
4. 2. NMR and HRMS Experiments 
a) Monitoring the course of the reaction between 3b
and GSH in DMF-d7/D2O:
A mixture of 3b (4.0 mg, 0.0014 mmol) and GSH
(5.7 mg, 0.0185 mM) was dissolved in DMF-d7 (0.50 mL)
and D2O (0.25 mL). The reaction mixture was kept at 23 °C
and 1H NMR spectra were recorded at the same tempera-
ture at the times indicated in Figure 4d. Resonances of
3b,14 3bRED, GSH and GSSG were assigned on the basis
of literature data and 2D 1H-1H COSY spectra of the reac-
tion mixture. After 44 h a drop of the reaction mixture was
dissolved in 0.1% formic acid in Milli-Q water (1 mL)
and left for 24 h to allow complete deuterium exchange.
HRMS spectrum was recorded, which revealed unreacted
GSH, GSSG and 3bRED (m/z found: 802.1886. Calcd. for
C26H30F3N8O6Pt
+ [M + H]+ = 802.1890).
b) Monitoring the course of the reaction between 3b
and GSH in a mixture of DMSO and growth medium with
fetal serum:
A mixture of 3b (1.1 mg, 0.0014 mmol) and GSH
(1.9 mg, 0.00618 mmol) was dissolved in DMSO (0.50
mL), diluted with growth medium supplemented with
10% fetal serum (0.20 mL) and kept at 23 °C. The reac-
tion was followed by dissolving an aliquot (one drop) in
acetonitrile (1 mL) and measuring HRMS spectra. 
4. 3. Cells
Human cervical carcinoma HeLa cells were obtai-
ned from cell culture bank (GIBCO BRL, Invitrogen,
Grand Island, USA). They were cultured as a monolayer
culture according in Dulbecco’s medium supplemented
with 10% fetal serum (Gibco BRL, Invitrogen, USA) and
cultured in a humidified atmosphere of 5% CO2 at 37 °C.
4. 4. Compounds
Carboplatin and cisplatin were dissolved in water
whereas compounds 1–8 were dissolved in DMSO. They
were and stored at –20 °C, and diluted to the appropriate
concentrations with growth medium just before use.
4. 5. Cytotoxicity Assay
Cytotoxic effect of compounds under investigation
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-dip-
henyltetrazolium bromide (MTT) (Sigma Aldrich, USA)
assay, modified as described. Cells were seeded into 96-
well tissue culture plates (3000 cells/0.18 mL me-
dium/well). Different concentrations of new compounds
were added (0.02 mL) to each well on the following day.
Each concentration was tested in quadruplicate. Follo-
wing 72 h incubation at 37 °C, the medium was aspirated,
and 20 mg of MTT dye/0.04 mL medium/well was added.
Four hours later, formazan crystals were dissolved in 
DMSO (0.17 mL/well), the plates were mechanically agi-
tated for 5 min and the optical density at 545 nm was de-
termined on a microtiter plate reader (Awareness Techno-
logy Inc, Palm City, FL). Each experiment was repeated
three times.
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Povzetek
Opisali smo knji`nico strukturno razli~nih cis-[Pt(2-pikolil-1,2,3-triazol)Cl2] in cis-[Pt(propan-1,3-diamin)CBDCA]
(CBDCA = 1,1-ciklobutandikarboksilat) kompleksov 1–4, funkcionaliziranih z diazenkarboksamidno skupino. Te spo-
jine ohranjajo oksidativne sposobnosti diazenkarboksamidov do glutationa, kar smo dokazali na osnovi NMR in HRMS
eksperimentov. Citotoksi~nost spojin 1–4 smo testirali na humanih tumorskih celicah materni~nega vratu HeLa. 
[tiri spojine so pokazale zmerno aktivnost. Prav tako smo testirali nekatere modelne spojine, od katerih je bil [PtCl2L2]
(L = 4-fenil-1-(2-pikolil)-1H-1,2,3-triazol) najbolj aktiven z IC50 = 19.05 μM, kar je primerljivo z aktivnostjo cisplatina
(IC50 = 16.3 μM).
